125 related articles for article (PubMed ID: 12473572)
21. A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
Gesundheit B; Shapira MY; Ackerstein A; Resnik IB; Bitan M; Or R
Acta Haematol; 2007; 117(2):119-21. PubMed ID: 17135719
[TBL] [Abstract][Full Text] [Related]
22. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
24. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
25. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
Berenson JR; Yeh HS
Clin Lymphoma Myeloma; 2006 Nov; 7(3):192-8. PubMed ID: 17229334
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide: an emerging therapy for multiple myeloma.
Munshi NC
Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Litzow MR; Lee S; Bennett JM; Dewald GW; Gallagher RE; Jain V; Paietta EM; Racevskis J; Rousey SR; Mazza JJ; Tallman MS
Haematologica; 2006 Aug; 91(8):1105-8. PubMed ID: 16870552
[TBL] [Abstract][Full Text] [Related]
28. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species.
Nakazato T; Ito K; Ikeda Y; Kizaki M
Clin Cancer Res; 2005 Aug; 11(16):6040-9. PubMed ID: 16115949
[TBL] [Abstract][Full Text] [Related]
29. [Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
Izdebska M; Grzanka A; Szczepański MA; Litwiniec A
Postepy Hig Med Dosw (Online); 2008 Sep; 62():463-7. PubMed ID: 18806735
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide: expanding roles for an ancient drug?
Ravandi F
Leukemia; 2004 Sep; 18(9):1457-9. PubMed ID: 15269784
[No Abstract] [Full Text] [Related]
31. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.
Sanaat Z; Rezazadeh M; Gharamaleki JV; Ziae JE; Esfahani A
Acta Med Iran; 2011; 49(8):504-8. PubMed ID: 22009804
[TBL] [Abstract][Full Text] [Related]
33. Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer.
Kälkner KM; Ullén A; Wersäll P; Cohn-Cedermark G
Acta Oncol; 2007; 46(6):862-3. PubMed ID: 17653913
[No Abstract] [Full Text] [Related]
34. Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid.
Li JJ; Tang Q; Li Y; Hu BR; Ming ZY; Fu Q; Qian JQ; Xiang JZ
Acta Pharmacol Sin; 2006 Aug; 27(8):1078-84. PubMed ID: 16867262
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3.
Hu XM; Hirano T; Oka K
Cancer Chemother Pharmacol; 2003 Jul; 52(1):47-58. PubMed ID: 12750841
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Chang JE; Voorhees PM; Kolesar JM; Ahuja HG; Sanchez FA; Rodriguez GA; Kim K; Werndli J; Bailey HH; Kahl BS
Hematol Oncol; 2009 Mar; 27(1):11-6. PubMed ID: 18668698
[TBL] [Abstract][Full Text] [Related]
37. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
38. Effects of arsenic trioxide on voltage-dependent potassium channels and on cell proliferation of human multiple myeloma cells.
Zhou J; Wang W; Wei QF; Feng TM; Tan LJ; Yang BF
Chin Med J (Engl); 2007 Jul; 120(14):1266-9. PubMed ID: 17697580
[No Abstract] [Full Text] [Related]
39. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
40. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
